Publicaciones en colaboración con investigadores/as de Pfizer (United States) (42)

2024

  1. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

    JACC: Advances, Vol. 3, Núm. 8

  2. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients

    Clinical and Translational Oncology

  3. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

    Revista Espanola de Cardiologia

  4. Use of digital health tools in inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 9

2023

  1. Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process

    Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1215-1240

  2. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study

    Microorganisms, Vol. 11, Núm. 11

2022

  1. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  2. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2021

  1. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey

    Neurology and Therapy, Vol. 10, Núm. 2, pp. 833-845

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  4. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review

    Rheumatology and Therapy, Vol. 8, Núm. 1, pp. 17-40

2020

  1. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  2. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762

  3. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2019

  1. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

  2. Report of a TREAT-NMD/World duchenne organisation meeting on dystrophin quantification methodology

    Journal of Neuromuscular Diseases

  3. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials

    Alzheimer's and Dementia, Vol. 14, Núm. 6, pp. 837-842

  2. MRI predictors of amyloid pathology: Results from the EMIF-AD Multimodal Biomarker Discovery study

    Alzheimer's Research and Therapy, Vol. 10, Núm. 1